Latest Genmab News & Updates

See the latest news and media coverage for Genmab. We track all announcements, press releases, and industry mentions in real time, all in one place.

Genmab

Therapeutic antibody developer

genmab.com

Headquarters: 2500 Valby, Denmark
Company type: Public company
Number of employees: 2,500–5,000

Last updated Today

Latest news about Genmab

In short: Genmab reported strong 2026 Q1 revenue growth, presented promising epcoritamab data at EHA, and received a NICE recommendation for Tivdak.

Company announcements

June 15 Genmab

Genmab announces major shareholder Orbis holds 4.99% voting rights

Orbis Investment Management Limited controlled 3,112,476 shares as of June 12, 2026, representing 4.99% of share capital.

June 15 Genmab

Genmab published its Articles of Association

The document is dated June 11, 2026 and available on the company website.

June 13 Genmab

Genmab presents high epcoritamab response rates in elderly DLBCL

Phase 2 monotherapy showed 67% ORR and 58% CR; epcoritamab plus R-mini-CHOP showed 93% ORR and 86% CR, with durable MRD negativity.

June 11 Genmab

Genmab presents EPCORE FL-1 subgroup data showing consistent efficacy

The combination of epcoritamab with R2 showed sustained efficacy and manageable safety across risk subgroups, regardless of baseline factors.

Media coverage

June 13 Yahoo

EHA26: Epcoritamab improves PFS but not OS in R/R LBCL

The Phase III EPCORE DLBCL-1 met one of the two endpoints, with Genmab set to discuss next steps with global regulatory authorities.

June 13 The Manila Times

Genmab Announces Epcoritamab Monotherapy and Epcoritamab-Based Combination Regimens Demonstrate High Response Rates in Elderly Patients with Newly Diagnosed Diffuse Large B ...

The results from both studies were presented in two poster presentations (abstracts PS2082 and PF1007) at the European Hematology Association (EHA) 2026 Congress held in...

June 13 Investing News Network

New TALVEY® plus DARZALEX FASPRO® data demonstrate the strength of a bispecific combination in earlier-line relapsed or refractory multiple myeloma | INN

In August 2012, Janssen Biotech, Inc. and Genmab A/S entered a worldwide agreement, which granted Janssen an exclusive license to develop, manufacture and commercialize daratumumab.

June 11 Yahoo Finance

Genmab's EPCORE Data Deepens Lymphoma Profile As Investors Weigh Upside

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or...

Never miss news about Genmab

Track Genmab and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Genmab competitors & trending companies

Browse news for competitors to Genmab and other trending companies.